Eli Lilly's Path to $1,200 Share Price by 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Market Share Growth: Eli Lilly has captured approximately 60% of the U.S. GLP-1 market, significantly enhancing its competitive position in the rapidly growing obesity and diabetes drug sector, especially against Novo Nordisk's early lead.
- International Market Expansion: In Q1 2026, Lilly's revenue outside the U.S. surged 81% year-over-year to $7.7 billion, indicating the rapid unlocking of international market potential, particularly with rising demand in countries like Germany and France.
- Optimistic Revenue Forecast: With Mounjaro and Zepbound generating nearly $13 billion in Q1 2026, if this growth trend continues, quarterly revenue could reach $16 billion to $17.5 billion by late 2026, positioning annual revenue targets between $60 billion and $70 billion.
- Competitive Risks Persist: While Lilly dominates the GLP-1 market, challenges from Novo Nordisk and the development of new oral obesity therapies could impact its market share and future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1125.270
Low
950.00
Averages
1192
High
1500
Current: 1125.270
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Path to $1,200 Share Price by 2026
- Market Share Growth: Eli Lilly has captured approximately 60% of the U.S. GLP-1 market, significantly enhancing its competitive position in the rapidly growing obesity and diabetes drug sector, especially against Novo Nordisk's early lead.
- International Market Expansion: In Q1 2026, Lilly's revenue outside the U.S. surged 81% year-over-year to $7.7 billion, indicating the rapid unlocking of international market potential, particularly with rising demand in countries like Germany and France.
- Optimistic Revenue Forecast: With Mounjaro and Zepbound generating nearly $13 billion in Q1 2026, if this growth trend continues, quarterly revenue could reach $16 billion to $17.5 billion by late 2026, positioning annual revenue targets between $60 billion and $70 billion.
- Competitive Risks Persist: While Lilly dominates the GLP-1 market, challenges from Novo Nordisk and the development of new oral obesity therapies could impact its market share and future growth prospects.
See More
Eli Lilly Controls 60% of GLP-1 Market, Eyes $70 Billion Revenue
- Market Share Growth: Eli Lilly now commands approximately 60% of the U.S. GLP-1 market, a remarkable feat that enhances its competitive position in the rapidly expanding obesity and diabetes drug sector, particularly against Novo Nordisk's Ozempic and Wegovy.
- International Market Potential: Lilly's Mounjaro has launched across Europe, the Middle East, Asia, and Latin America, with international sales soaring 81% year-over-year to $7.7 billion in Q1 2026, highlighting significant market opportunities driven by rising global obesity rates.
- Revenue Expectations: The GLP-1 franchise is projected to achieve annual revenues between $60 billion and $70 billion, supported by nearly $13 billion in Q1 revenue, suggesting that with continued prescription growth and international expansion, this target is attainable.
- Competitive Risks: While Lilly maintains a dominant position in the GLP-1 market, competition from Novo Nordisk and new oral obesity therapies from competitors like Viking Therapeutics and Pfizer pose ongoing threats, necessitating continuous innovation to sustain market leadership.
See More
Novo Nordisk and Eli Lilly Intensify Competition in GLP-1 Market
- Intensifying Market Competition: Novo Nordisk's Wegovy pill saw a strong start in Q1 2026, with prescriptions skyrocketing from 1.3 million to 2 million, indicating robust market demand despite competitive pressures from Eli Lilly.
- Sales Challenges: Novo Nordisk warned that 2026 would be tough, with impending patent expiration in India and price cuts in the U.S. potentially impacting sales, although management believes volume will offset price pressures in the long run.
- Investment Appeal: With a dividend yield of 3.9% compared to Eli Lilly's 0.6%, Novo Nordisk presents a more attractive option for long-term investors, especially given its reasonable payout ratio of around 40%.
- Market Opportunities: Despite the risks, the early success of Novo Nordisk's Wegovy pill suggests that investors may be overlooking significant long-term opportunities in the GLP-1 market, particularly in the highly competitive pharmaceutical sector.
See More
Intensifying Competition in GLP-1 Weight Loss Drug Market
- Market Competition Analysis: Novo Nordisk's GLP-1 weight-loss drug Wegovy launched a new pill form in 2026, achieving 1.3 million prescriptions in Q1, which quickly rose to 2 million, indicating strong market demand and potential for long-term growth opportunities for the company.
- Financial Performance Comparison: Over the past three years, Novo Nordisk's stock has fallen by 40%, while Eli Lilly's has risen by over 150%, reflecting Eli Lilly's competitive advantage in the GLP-1 market, particularly regarding drug efficacy.
- Patent and Pricing Pressure: Novo Nordisk faces challenges with patent expiration in India and has been forced to cut prices in the U.S. market, putting pressure on sales; however, management expects volume growth from the Wegovy pill to offset the impact of price declines.
- Investor Focus: With a dividend yield of 3.9% compared to Eli Lilly's 0.6%, Novo Nordisk presents an attractive opportunity for long-term investors, despite the intense competition in the industry, as early successes suggest the company still has potential for future growth.
See More
Quantum Stocks Decline While Consumer Staples Rise
- Quantum Stocks Struggle: Quantinuum's debut on Nasdaq was lackluster, closing flat and subsequently dropping over 8% on Friday, falling below its IPO price of $60 per share, indicating market caution towards the quantum computing sector which may impact future funding and investor confidence.
- Consumer Staples Surge: Amid Friday's market sell-off, the consumer staples sector rose 2%, with companies like Colgate-Palmolive, Coca-Cola, and Procter & Gamble gaining over 3%, reflecting investor preference for defensive stocks, which could lead to a shift in capital towards these stable industries.
- Strong Performance in Medical Devices: Cooper Companies reported second-quarter adjusted earnings of $1.21 per share, exceeding the $1.10 consensus estimate, with revenue of $1.08 billion surpassing the $1.05 billion forecast, showcasing robust performance in the medical device sector that may attract more investor interest.
- Software Stocks Outlook Weakens: Docusign's outlook failed to impress, with shares slipping 6% as it projected second-quarter revenue between $865 million and $869 million, slightly below consensus, potentially affecting its future market performance and investor confidence.
See More
US Stocks Retreat as Tech Sector Faces Pressure
- Job Data Impact: Non-farm payrolls rose by 172,000 in May, exceeding expectations, while the unemployment rate held steady at 4.3%, leading to increased Treasury yields and heightened market expectations for a rate hike, negatively impacting stocks.
- Chip Stock Investment Opportunity: Jim Cramer highlighted that despite the tech sector's pullback, this presents a good opportunity to buy chip stocks, particularly Intel, which fell 6% on Friday, indicating that confidence in the sector remains strong.
- CrowdStrike Stock Decline: CrowdStrike's stock fell another 3.4% on Friday, with the CEO stating that expectations for earnings boosts from Anthropic's AI model are premature; Jim believes this pullback offers a buying opportunity for new investors, anticipating significant growth this quarter.
- Upcoming IPOs: SpaceX's IPO is set for next Friday, and although the S&P announced no index adjustments, Jim remains cautious about investors potentially selling existing holdings to make room for SpaceX, especially with Anthropic and OpenAI IPOs also on the horizon.
See More
Eli Lilly's Path to $1,200 Share Price by 2026
- Market Share Growth: Eli Lilly has captured approximately 60% of the U.S. GLP-1 market, significantly enhancing its competitive position in the rapidly growing obesity and diabetes drug sector, especially against Novo Nordisk's early lead.
- International Market Expansion: In Q1 2026, Lilly's revenue outside the U.S. surged 81% year-over-year to $7.7 billion, indicating the rapid unlocking of international market potential, particularly with rising demand in countries like Germany and France.
- Optimistic Revenue Forecast: With Mounjaro and Zepbound generating nearly $13 billion in Q1 2026, if this growth trend continues, quarterly revenue could reach $16 billion to $17.5 billion by late 2026, positioning annual revenue targets between $60 billion and $70 billion.
- Competitive Risks Persist: While Lilly dominates the GLP-1 market, challenges from Novo Nordisk and the development of new oral obesity therapies could impact its market share and future growth prospects.
See More
Eli Lilly Controls 60% of GLP-1 Market, Eyes $70 Billion Revenue
- Market Share Growth: Eli Lilly now commands approximately 60% of the U.S. GLP-1 market, a remarkable feat that enhances its competitive position in the rapidly expanding obesity and diabetes drug sector, particularly against Novo Nordisk's Ozempic and Wegovy.
- International Market Potential: Lilly's Mounjaro has launched across Europe, the Middle East, Asia, and Latin America, with international sales soaring 81% year-over-year to $7.7 billion in Q1 2026, highlighting significant market opportunities driven by rising global obesity rates.
- Revenue Expectations: The GLP-1 franchise is projected to achieve annual revenues between $60 billion and $70 billion, supported by nearly $13 billion in Q1 revenue, suggesting that with continued prescription growth and international expansion, this target is attainable.
- Competitive Risks: While Lilly maintains a dominant position in the GLP-1 market, competition from Novo Nordisk and new oral obesity therapies from competitors like Viking Therapeutics and Pfizer pose ongoing threats, necessitating continuous innovation to sustain market leadership.
See More
Novo Nordisk and Eli Lilly Intensify Competition in GLP-1 Market
- Intensifying Market Competition: Novo Nordisk's Wegovy pill saw a strong start in Q1 2026, with prescriptions skyrocketing from 1.3 million to 2 million, indicating robust market demand despite competitive pressures from Eli Lilly.
- Sales Challenges: Novo Nordisk warned that 2026 would be tough, with impending patent expiration in India and price cuts in the U.S. potentially impacting sales, although management believes volume will offset price pressures in the long run.
- Investment Appeal: With a dividend yield of 3.9% compared to Eli Lilly's 0.6%, Novo Nordisk presents a more attractive option for long-term investors, especially given its reasonable payout ratio of around 40%.
- Market Opportunities: Despite the risks, the early success of Novo Nordisk's Wegovy pill suggests that investors may be overlooking significant long-term opportunities in the GLP-1 market, particularly in the highly competitive pharmaceutical sector.
See More
Intensifying Competition in GLP-1 Weight Loss Drug Market
- Market Competition Analysis: Novo Nordisk's GLP-1 weight-loss drug Wegovy launched a new pill form in 2026, achieving 1.3 million prescriptions in Q1, which quickly rose to 2 million, indicating strong market demand and potential for long-term growth opportunities for the company.
- Financial Performance Comparison: Over the past three years, Novo Nordisk's stock has fallen by 40%, while Eli Lilly's has risen by over 150%, reflecting Eli Lilly's competitive advantage in the GLP-1 market, particularly regarding drug efficacy.
- Patent and Pricing Pressure: Novo Nordisk faces challenges with patent expiration in India and has been forced to cut prices in the U.S. market, putting pressure on sales; however, management expects volume growth from the Wegovy pill to offset the impact of price declines.
- Investor Focus: With a dividend yield of 3.9% compared to Eli Lilly's 0.6%, Novo Nordisk presents an attractive opportunity for long-term investors, despite the intense competition in the industry, as early successes suggest the company still has potential for future growth.
See More
Quantum Stocks Decline While Consumer Staples Rise
- Quantum Stocks Struggle: Quantinuum's debut on Nasdaq was lackluster, closing flat and subsequently dropping over 8% on Friday, falling below its IPO price of $60 per share, indicating market caution towards the quantum computing sector which may impact future funding and investor confidence.
- Consumer Staples Surge: Amid Friday's market sell-off, the consumer staples sector rose 2%, with companies like Colgate-Palmolive, Coca-Cola, and Procter & Gamble gaining over 3%, reflecting investor preference for defensive stocks, which could lead to a shift in capital towards these stable industries.
- Strong Performance in Medical Devices: Cooper Companies reported second-quarter adjusted earnings of $1.21 per share, exceeding the $1.10 consensus estimate, with revenue of $1.08 billion surpassing the $1.05 billion forecast, showcasing robust performance in the medical device sector that may attract more investor interest.
- Software Stocks Outlook Weakens: Docusign's outlook failed to impress, with shares slipping 6% as it projected second-quarter revenue between $865 million and $869 million, slightly below consensus, potentially affecting its future market performance and investor confidence.
See More
US Stocks Retreat as Tech Sector Faces Pressure
- Job Data Impact: Non-farm payrolls rose by 172,000 in May, exceeding expectations, while the unemployment rate held steady at 4.3%, leading to increased Treasury yields and heightened market expectations for a rate hike, negatively impacting stocks.
- Chip Stock Investment Opportunity: Jim Cramer highlighted that despite the tech sector's pullback, this presents a good opportunity to buy chip stocks, particularly Intel, which fell 6% on Friday, indicating that confidence in the sector remains strong.
- CrowdStrike Stock Decline: CrowdStrike's stock fell another 3.4% on Friday, with the CEO stating that expectations for earnings boosts from Anthropic's AI model are premature; Jim believes this pullback offers a buying opportunity for new investors, anticipating significant growth this quarter.
- Upcoming IPOs: SpaceX's IPO is set for next Friday, and although the S&P announced no index adjustments, Jim remains cautious about investors potentially selling existing holdings to make room for SpaceX, especially with Anthropic and OpenAI IPOs also on the horizon.
See More
